{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:30:50Z","timestamp":1793129450216,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"unspecified","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH","award":["PO1 CA23766"],"award-info":[{"award-number":["PO1 CA23766"]}]},{"name":"NIH","award":["R35 CA241894"],"award-info":[{"award-number":["R35 CA241894"]}]},{"name":"NCI","award":["1R50CA265328-01A1"],"award-info":[{"award-number":["1R50CA265328-01A1"]}]},{"name":"Sunshine fund","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antigen loss and tumor heterogeneity present significant challenges for successful immunotherapies. T-cell receptor (TCR)-based therapies rely on the recognition of epitopes derived from intracellular tumor proteins presented by major histocompatibility complex class I molecules on cell surface. Solid tumor cells frequently lack immunoproteasomes, which are crucial for processing and presenting certain immunogenic epitopes. An effective strategy to mitigate the risk of antigen absence and tumor heterogeneity is to simultaneously target multiple tumor antigens, thereby providing critical rescue from disease relapse. Previously, we engineered a TCR mimic monoclonal antibody (TCRm) \u201cESK2\u201d, specific for Wilm\u2019s tumor 1 (WT1)-derived epitope RMFPNAPYL (RMF) in the context of HLA-A2, into a new chimeric antigen receptor T-cell format, antibody-TCR receptor (AbTCR)-chimeric signaling receptor (CSR). However, the RMF epitope is largely dependent on processing by the immunoproteasomes, which can be lost from leukemia cells and sometimes absent in solid tumor cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To mitigate antigen loss, tumor heterogeneity and broaden the reach of AbTCR T cells, we combined ESK2 with a new TCRm for an immunoproteosome-independent epitope derived from WT1, VLDFAPPGA (VLD), in the context of HLA-A2 molecules, named ESK3. ESK2 and ESK3 were tandemly engineered into one AbTCR-CSR construct, simultaneously recognizing both the WT1 RMF and VLD epitopes. To add additional specificity and potency, a CSR in these cells was engineered with a single chain variable fragment (scFv) for either CD33 to treat leukemia or mesothelin to treat solid tumors. The specificity and efficacy of the AbTCR-CSRs were evaluated in both in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro studies demonstrated that the Tri-AbTCR-CSR (CD33 CSR) T cells showed the best killing activity against most acute myeloid leukemia cells. Similar levels of cytotoxicity were exhibited by ESK3 AbTCR-CSR (mesothelin CSR) against most solid tumor cell lines when compared with the Tri-AbTCR or a combination of ESK2 and ESK3 AbTCR-CSR. In animal therapy models, trispecific AbTCR-CSR T cells showed efficacy equivalent to single ESK2-AbTCR or ESK3-AbTCR-CSR T cells, against hematopoietic or solid tumor cells, further supporting the advantage of triple targeting strategy, overcoming epitope loss variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Trispecific T cells targeting immunoproteasome-dependent and independent epitopes of WT1 peptide\/HLA-A2 complexes, plus a CSR recognizing a third tumor-associated antigen, present an effective and cost-efficient approach for overcoming tumor immune evasion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013685","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:40:16Z","timestamp":1768405216000},"page":"e013685","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escape"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-6283","authenticated-orcid":false,"given":"Tao","family":"Dao","sequence":"first","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc, Emeryville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Meyerberg","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita","family":"Aretz","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5814-0705","authenticated-orcid":false,"given":"Akihiko","family":"Shiiya","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Korontsvit","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbao","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc, Emeryville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyou","family":"Cui","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc, Emeryville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Panchwagh","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson","family":"Cai","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Zhan","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc, Emeryville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Eureka Therapeutics Inc, Emeryville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026011407400991000_14.1.e013685.1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568"},{"key":"2026011407400991000_14.1.e013685.2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0598-2"},{"key":"2026011407400991000_14.1.e013685.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102329"},{"key":"2026011407400991000_14.1.e013685.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00175","article-title":"Antigen Loss Variants: Catching Hold of Escaping Foes","volume":"8","author":"Vyas","year":"2017","journal-title":"Front Immunol"},{"key":"2026011407400991000_14.1.e013685.5","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1182\/bloodadvances.2021006069","article-title":"Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment","volume":"6","author":"Bourne","year":"2022","journal-title":"Blood Adv"},{"key":"2026011407400991000_14.1.e013685.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00339-z"},{"key":"2026011407400991000_14.1.e013685.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0737"},{"key":"2026011407400991000_14.1.e013685.8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyp194"},{"key":"2026011407400991000_14.1.e013685.9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.7"},{"key":"2026011407400991000_14.1.e013685.10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026011407400991000_14.1.e013685.11","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.693744"},{"key":"2026011407400991000_14.1.e013685.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0708"},{"key":"2026011407400991000_14.1.e013685.13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92335"},{"key":"2026011407400991000_14.1.e013685.14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8070","article-title":"Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency","volume":"14","author":"Lahman","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026011407400991000_14.1.e013685.15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8027","article-title":"CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function","volume":"14","author":"Ruggiero","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026011407400991000_14.1.e013685.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004409","article-title":"WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma","volume":"10","author":"van Amerongen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026011407400991000_14.1.e013685.17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.2023021054","article-title":"A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML","volume":"143","author":"Dao","year":"2024","journal-title":"Blood"},{"key":"2026011407400991000_14.1.e013685.18","doi-asserted-by":"publisher","DOI":"10.1038\/nri3279"},{"key":"2026011407400991000_14.1.e013685.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.013"},{"key":"2026011407400991000_14.1.e013685.20","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.517","article-title":"Total Internal Reflection Fluorescence (TIRF) Microscopy","volume":"2","author":"Fish","year":"2022","journal-title":"Curr Protoc"},{"key":"2026011407400991000_14.1.e013685.21","doi-asserted-by":"crossref","first-page":"176ra133","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026011407400991000_14.1.e013685.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.020"},{"key":"2026011407400991000_14.1.e013685.23","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0020"},{"key":"2026011407400991000_14.1.e013685.24","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","article-title":"Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1","volume":"72","author":"Mun","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026011407400991000_14.1.e013685.25","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24678","article-title":"Approaching untargetable tumor-associated antigens with antibodies","volume":"2","author":"Dao","year":"2013","journal-title":"Oncoimmunology"},{"key":"2026011407400991000_14.1.e013685.26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1049803","article-title":"T cell receptor mimic antibodies for cancer therapy","volume":"5","author":"Dubrovsky","year":"2016","journal-title":"Oncoimmunology"},{"key":"2026011407400991000_14.1.e013685.27","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3349"},{"key":"2026011407400991000_14.1.e013685.28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14712598.2016.1176138","article-title":"Opportunities and challenges for TCR mimic antibodies in cancer therapy","volume":"16","author":"Chang","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2026011407400991000_14.1.e013685.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01567-w"},{"key":"2026011407400991000_14.1.e013685.30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:40:20Z","timestamp":1768405220000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jitc-2025-013685"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013685","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}